tiprankstipranks
Coherus Biosciences upgraded to Buy from Neutral at UBS
The Fly

Coherus Biosciences upgraded to Buy from Neutral at UBS

UBS analyst Ashwani Verma upgraded Coherus Biosciences to Buy from Neutral with an unchanged price target of $11. The recent selloff in shares presents an attractive entry point as the company’s "topline growth narrative" appears underappreciated at current valuation levels, the analyst tells investors in a research note. Through its multiple biosimilar launches, Coherus has "multiple shots on goal," says the firm. It believes the company’s biosimilar revenue can climb to $580M by 2025 from $211M in 2022.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on CHRS:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles